desmopressin acetate · Ferring Pharms Inc · NDA 022517
Nocdurna
Earliest generic entry, as listed · earliest of 2 marketed strengths
13 Apr 2030
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9974826, US 9974826. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9974826 | use U-2326 | 13 Apr 2030 |
| US 9974826 | use U-2327 | 13 Apr 2030 |
| US 10137167 | use U-2327 | 21 May 2029 |
| US 11020448 | use U-2327 | 21 May 2029 |
| US 11963995 | use U-2327 | 21 May 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022517 · 001 · RLD · discontinued | tablet, sublingual | 0.0277MG | 13 Apr 2030 |
| 022517 · 002 · RLD · discontinued | tablet, sublingual | 0.0553MG | 13 Apr 2030 |